Interestingly, the integral role of BIM in promoting apoptosis in response to molecular targeted therapies has been determined in BRAF-mutant colorectal cancer cells [65], BRAF-mutated melanoma cells [66], BCR–ABL-positive leukemia cells [67], and EML4-ALK-positive NSCLC cells [68]. Here, BCL2L11 is linked to non-small cell lung carcinoma.